Jun 2026 (Q2 FY26) — Aug 13, 2026
MediWound Q2 FY26 — EscharEx Phase III Progress & NexoBrid Commercial Traction
Read the full callMediWound (MDWD) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
MediWound earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Price
$12.7 +7.17% · +$0.85
Performance −32.4% 1Y
1Y: $18.8 on 17 Oct 2025 → $12.7. High $19.69 (20 Oct 2025), low $11.85 (16 Oct 2026).
- Previous close
- $11.85
- 52-week range
- $11.85 – $19.69
- One year
- −35.50%
Overview
- Symbol
- MDWD
- Sector
- Health Care
- Industry
- Medicinal Chemicals & Botanical Products
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 27, 2026
MediWound Q1 FY26 — EscharEx Enrollment Progresses, NexoBrid BARDA Contract Secured
Read the full callEvery analysed call
MediWound earnings calls (MDWD)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | — | — | 24 | 24 | 39 | 35 | 42 | 43 |
| Fixed assets | 2 | 2 | 3 | 2 | 2 | 9 | 14 | 19 |
| Total assets | 35 | 41 | 31 | 20 | 50 | 66 | 73 | 86 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | 8 | -7 | -9 | -12 | -10 | -14 | -16 |
| Cash from investing | -17 | -7 | 17 | 4 | -0 | -34 | -8 | -18 |
| Cash from financing | 0 | -1 | -1 | -1 | 36 | 23 | 19 | 30 |
| Net cash flow | -29 | 3 | 10 | -6 | 23 | -22 | -3 | -4 |
| Capital expenditure | -1 | -1 | -1 | -0 | -1 | -6 | -6 | -6 |
| Free cash flow | -13 | 7 | -8 | -9 | -12 | -17 | -20 | -22 |
Insider filings
11 filings between May 29, 2026 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
$142.7K
7 purchases by 3 insiders
Sales
$82.1K
4 sales by 2 insiders
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| SHAMIR NACHUM | $84.0K | — | Jun 3, 2026 |
| Hess Shmuel | — | $75.4K | Aug 27, 2026 |
| Fox David Morton | $49.9K | — | Jun 1, 2026 |
| Rubinstein Samuel | $8.8K | $6.7K | Sep 1, 2026 |
Latest filings (11)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Rubinstein Samuel Director | Purchase | 525 | $6.6K |
| Sep 1, 2026 | Rubinstein Samuel Director | Sale | 525 | $6.7K |
| Aug 27, 2026 | Hess Shmuel COO & Chief Commercial Officer | Sale | 1,979 | $25.2K |
| Aug 27, 2026 | Hess Shmuel COO & Chief Commercial Officer | Sale | 1,979 | $26.0K |
| Aug 26, 2026 | Hess Shmuel COO & Chief Commercial Officer | Sale | 1,865 | $24.2K |
| Jun 3, 2026 | SHAMIR NACHUM Director | Purchase | 175 | $2.4K |
| Jun 3, 2026 | SHAMIR NACHUM Director | Purchase | 5,825 | $81.5K |
| Jun 1, 2026 | Fox David Morton Director | Purchase | 1,797 | $25.1K |
| Jun 1, 2026 | Fox David Morton Director | Purchase | 10 | $142 |
| Jun 1, 2026 | Fox David Morton Director | Purchase | 1,730 | $24.6K |
| May 29, 2026 | Rubinstein Samuel Director | Purchase | 150 | $2.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MediWound Ltd.
Free account. Everything above stays public.
Write why you follow MediWound Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading